[go: up one dir, main page]

MX2017010009A - Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas. - Google Patents

Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas.

Info

Publication number
MX2017010009A
MX2017010009A MX2017010009A MX2017010009A MX2017010009A MX 2017010009 A MX2017010009 A MX 2017010009A MX 2017010009 A MX2017010009 A MX 2017010009A MX 2017010009 A MX2017010009 A MX 2017010009A MX 2017010009 A MX2017010009 A MX 2017010009A
Authority
MX
Mexico
Prior art keywords
influenza
virus
binding molecules
strain
directed against
Prior art date
Application number
MX2017010009A
Other languages
English (en)
Inventor
Vogels Ronald
Heinz Edward Friesen Robert
Brandenburg Boerries
A Kolkman Joost
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of MX2017010009A publication Critical patent/MX2017010009A/es

Links

Classifications

    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a moléculas de unión monoméricas y multiméricas que pueden unirse específicamente a hemaglutinina (HA) de al menos dos cepas del virus influenza A, comprendiendo dichas cepas HA de dos subtipos de HA diferentes del grupo filogenético 2; o que pueden unirse específicamente a hemaglutinina (HA) de al menos una cepa del virus influenza A del grupo filogenético 1 y al menos una cepa del virus influenza A del grupo filogenético 2; o que pueden unirse específicamente a hemaglutinina (HA) de al menos una cepa del virus influenza B. Las moléculas de unión preferiblemente también pueden neutralizar al menos dos cepas del virus influenza A del grupo filogenético 2; o pueden neutralizar al menos una cepa del virus influenza A del grupo filogenético 1 y al menos una cepa del virus influenza A del grupo filogenético 2; o pueden neutralizar específicamente al menos una cepa del virus influenza B.
MX2017010009A 2015-02-05 2016-02-05 Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas. MX2017010009A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153957 2015-02-05
PCT/EP2016/052556 WO2016124768A1 (en) 2015-02-05 2016-02-05 Binding molecules directed against influenza hemagglutinin and uses thereof

Publications (1)

Publication Number Publication Date
MX2017010009A true MX2017010009A (es) 2017-10-24

Family

ID=52484335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010009A MX2017010009A (es) 2015-02-05 2016-02-05 Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas.

Country Status (17)

Country Link
US (3) US10370435B2 (es)
EP (1) EP3253411A1 (es)
JP (2) JP6772157B2 (es)
KR (1) KR20170107562A (es)
CN (1) CN107207611B (es)
AU (1) AU2016214304B2 (es)
BR (1) BR112017016417A2 (es)
CA (1) CA2975655C (es)
EA (1) EA038407B1 (es)
HK (1) HK1243925A1 (es)
IL (1) IL253653B (es)
MX (1) MX2017010009A (es)
MY (1) MY186585A (es)
PH (1) PH12017501216B1 (es)
SG (2) SG10202103618XA (es)
WO (1) WO2016124768A1 (es)
ZA (1) ZA201705300B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
PH12017501216B1 (en) * 2015-02-05 2023-05-24 Janssen Vaccines And Prevention B V Binding molecules directed against influenza hemagglutinin and uses thereof
EP3307310A2 (en) 2015-05-13 2018-04-18 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
CN119060177A (zh) 2016-05-20 2024-12-03 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN110234337A (zh) * 2016-10-27 2019-09-13 扬森疫苗与预防公司 中和流感病毒的化合物
MX2019006043A (es) 2016-11-23 2019-09-26 Harpoon Therapeutics Inc Proteína de unión de antígeno prostático específico de membrana.
AU2017363302A1 (en) 2016-11-23 2019-06-27 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用
AU2018227440B2 (en) 2017-02-28 2024-06-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
JP2020510430A (ja) 2017-02-28 2020-04-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ａａｖベクターに基づくインフルエンザワクチン
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
BR112019023856A2 (pt) 2017-05-12 2020-06-09 Harpoon Therapeutics Inc proteínas triespecíficas que visam msln e métodos de utilização
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
BR112020007196A2 (pt) 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
JP2021523192A (ja) 2018-05-14 2021-09-02 ハープーン セラピューティクス，インク． 免疫グロブリン分子の条件的活性化のための結合部分
JP7162190B2 (ja) * 2018-07-17 2022-10-28 パナソニックＩｐマネジメント株式会社 インフルエンザウィルス核内蛋白質に結合する抗体、複合体、それを用いた検出装置及び検出方法
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
US20240317841A1 (en) * 2020-11-23 2024-09-26 Vir Biotechnology, Inc. Antibodies against influenza a viruses
CA3174330A1 (en) * 2021-03-31 2022-09-30 Shugang YAO Binding agents targeting tumors and/or immune cells
WO2024073435A2 (en) * 2022-09-27 2024-04-04 Anwita Biosciences, Inc. Anti-lag-3/il-2 fusion proteins, encoding polynucleotides, pharmaceutical compositions, and therapeutic applications
KR20250139326A (ko) * 2023-02-01 2025-09-23 안위타 바이오사이언시스, 인코포레이티드 항-pd-1/il-2 융합 단백질, 약제학적 조성물, 및 치료적 적용
WO2025125577A1 (en) * 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
CN117924470B (zh) * 2023-12-14 2024-09-20 南京大学 一种靶向甲型流感病毒核蛋白纳米抗体的制备方法和应用
WO2026022067A1 (en) 2024-07-20 2026-01-29 Leyden Laboratories B.V. Neutralising antibodies against influenza viruses
CN119874923B (zh) * 2025-03-27 2025-08-22 哈尔滨医科大学 一种靶向Nectin-4的纳米抗体、结合分子及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
SI1161548T2 (sl) 1999-04-15 2010-02-26 Crucell Holland Bv Priprava rekombinantnega proteina v humani celici z uporabo sekvenc, ki kodirajo adenovirusni E1 protein
GB0522460D0 (en) 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
AU2009228058A1 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
WO2009147248A2 (en) * 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US8734803B2 (en) * 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US8563305B2 (en) 2009-04-30 2013-10-22 Oklahoma Medical Research Foundation Rapid generation of antibodies
CN102276719B (zh) * 2010-06-09 2014-12-24 中国科学院生物物理研究所 禽流感病毒单域抗体、五聚抗体及其制备和应用
CN102023212B (zh) 2010-09-28 2014-04-02 汕头大学医学院 一种流感病毒神经氨酸酶抗体的快速检测方法
EA027054B1 (ru) * 2011-07-14 2017-06-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
LT3418300T (lt) * 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas
GB201115214D0 (en) * 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
WO2013132007A1 (en) 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
US9650434B2 (en) * 2013-04-02 2017-05-16 Xiamen University Broad-spectrum monoclonal antibody recognizing HA1 domain of hemagglutinin of influenza virus
PH12017501216B1 (en) * 2015-02-05 2023-05-24 Janssen Vaccines And Prevention B V Binding molecules directed against influenza hemagglutinin and uses thereof

Also Published As

Publication number Publication date
AU2016214304B2 (en) 2021-11-11
US11136379B2 (en) 2021-10-05
US20200299364A1 (en) 2020-09-24
SG10202103618XA (en) 2021-05-28
CA2975655A1 (en) 2016-08-11
PH12017501216A1 (en) 2018-01-15
AU2016214304A1 (en) 2017-07-20
US10370435B2 (en) 2019-08-06
CN107207611A (zh) 2017-09-26
CN107207611B (zh) 2021-11-09
EP3253411A1 (en) 2017-12-13
WO2016124768A1 (en) 2016-08-11
JP6772157B2 (ja) 2020-10-21
CA2975655C (en) 2023-09-19
US20180016323A1 (en) 2018-01-18
JP2018505677A (ja) 2018-03-01
IL253653B (en) 2021-10-31
US10703804B2 (en) 2020-07-07
IL253653A0 (en) 2017-09-28
JP2020171288A (ja) 2020-10-22
SG11201705614QA (en) 2017-08-30
ZA201705300B (en) 2021-05-26
MY186585A (en) 2021-07-28
KR20170107562A (ko) 2017-09-25
HK1243925A1 (zh) 2018-07-27
EA038407B1 (ru) 2021-08-24
EA201791735A1 (ru) 2017-11-30
PH12017501216B1 (en) 2023-05-24
US20190359693A1 (en) 2019-11-28
BR112017016417A2 (pt) 2018-03-27

Similar Documents

Publication Publication Date Title
MX2017010009A (es) Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas.
CR20110084A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
MX2016004067A (es) Anticuerpo anti-influenza a neutralizantes y usos de los mismos.
BR112016022113A2 (pt) anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso
MX360056B (es) Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
MX380393B (es) Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
EA201790571A1 (ru) Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа
EP2812348A4 (en) COMPREHENSIVELY OPTIMIZED, WIDE-REACTIVE ANTIGEN FOR H3N2, H2N2 AND B INFLUENZA VIRUSES
MX2017015189A (es) Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
PH12014500369A1 (en) Influenza h5 vaccines
MX2017000595A (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
EA201890322A1 (ru) Новый вид тобамовируса
EP3625349A4 (en) MODIFIED VIRUSES
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
KR101921384B9 (ko) 인플루엔자 바이러스 표면 단백질 헤마글루티닌 단량체를 포함하는 오소믹소바이러스에 대한 항원 조성물
EP3423051A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF THE INFLUENZA VIRUS
EA201790778A1 (ru) Фармацевтические композиции длительного действия от гепатита с
MX360137B (es) Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
RU2016146943A (ru) Квадривалентная живая гриппозная вакцина для профилактики сезонного гриппа